智通财经APP讯，英派药业-B(07630)发布公告，有关全球发售的稳定价格期于2026年6月7日(星期日)(即递交香港公开发售申请截止日期后第30日)结束。稳定价格操作人高盛(亚洲)有限责任公司或其联属人士或代其行事的任何人士于稳定价格期进行的稳定价格行动载列如下：
(1)于国际发售超额分配合共629.64万股H股，占于任何超额配股权获行使前全球发售项下初步可供认购的发售股份总数约15%;及
(2)整体协调人(为其本身及代表国际包销商)于2026年6月5日(星期五)按每股H股20.10港元(即全球发售项下每股H股的发售价，不包括1%经纪佣金、0.0027%证监会交易征费、0.00565%联交所交易费及0.00015%会财局交易征费)悉数行使超额配股权，涉及合共629.64万股H股，以加快向同意延迟交付其根据全球发售认购的相关H股的承配人交付部分H股。
于稳定价格期，稳定价格操作人并无出于稳定价格的目的在市场上购入或出售任何H股。
紧随超额配股权获悉数行使及稳定价格期结束后，本公司将继续遵守上市规则第19A.28B(1)条的公众持股量规定。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.